Study Exposures, Outcomes:
|
|
- Britney Craig
- 5 years ago
- Views:
Transcription
1 GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic reaction/ angioedema Rationale: Review of post marketing safety data identified spontaneous adverse event reports describing serious hypersensitivity reactions after initiation of Coreg CR (carvedilol phosphate) by patients who were previously treated with Coreg IR (carvedilol). Objectives: The objectives of the study are as follows: 1. To provide crude estimates of the incidence rates of hypersensitivity reactions for Coreg IR, Coreg CR, long acting beta blockers (LA propranolol and S.A. metoprolol), other α1/β-adrenergic antagonists (excluding Coreg IR and Coreg CR, i.e., labetalol), short acting non-selective beta-blockers and short acting β1-selective agents, ACEi, ACEi plus Coreg IR, ACEi plus Coreg CR and ACEi plus (long acting beta blockers, labetolol, short acting non-selective beta-blockers or short acting β1-selective agents) 2. To assess whether Coreg CR is associated with a higher risk of hypersensitivity reactions (anaphylactic reaction/ angioedema) compared to Coreg IR. 3. To assess whether Coreg CR is associated with a higher risk of hypersensitivity reactions (anaphylactic reaction/ angioedema) compared to other long acting B-blockers. 4. To assess whether switching from Coreg IR to Coreg CR is associated with a higher risk of hypersensitivity reactions (anaphylactic reaction/ angioedema) compared to switching from Coreg IR to other long acting B- blockers. Indication: Congestive Heart Failure, Left ventricular dysfunction following myocardial infarction, and hypertension Study Investigators/Centers: GSK Research Methods: Data Source: The LabRx Database (referred to in publications as the i3 InVision Data Mart ), which is provided by Ingenix Pharmaceutical Services, Inc. It is a comprehensive, de-identified U.S. healthcare claims database that contains the aggregated health claims experience of the covered lives managed by United Healthcare. Overall, it is representative of the non-elderly, insurance-carrying population in the U.S., but it also contains information on several hundred thousand Managed Medicaid and Medicare Advantage members. It contains only those covered lives for which there exists a combined benefit structure including medical and prescription coverage. The database is geographically diverse, including data for members in all 50 states. It contains inpatient, outpatient and pharmacy claims, lab results and enrollment information on over 23.3 million lives from October 2004 through September In addition, the LabRx database includes and integrates the outpatient test result values for lab tests processed by the two largest national lab vendors. Study Design: case control analysis nested within a cohort of beta-blocker users. Study Population: Subjects who have at least one prescription claim for a beta-blocker in the LabRx database from Oct. 1 st 2004 to Sep. 30 th 2007 and at least one month of enrollment in the healthcare plan were eligible for the study. Selection of cases and controls Cases: Incident cases of hypersensitivity reactions with an ICD-9 diagnostic code of (other anaphylactic shock) or (angioneurotic edema). The date of the event was defined as the index date. Controls: For each subject defined as a case, three controls were matched to the case on age (+/- 5 years), gender, and year of first beta-blocker use. Controls were selected at random from the pool of eligible controls for each case. Controls were subjects with a treatment with beta-blocker who did not have a diagnosis of hypersensitivity reaction at any time during their follow-up in the database. Control patients were assigned the same index date as the case patients to which they are matched. Study Exposures, Outcomes: Exposure definition and Measures Subjects were classified according to their beta blocker and ACEi exposure. Subjects were considered exposed if their beta-blocker or ACEi prescription date was within 1 month prior to the index date. Drug exposure was inferred from prescription claims. The following 11 mutually exclusive drug exposure categories were created: 1. Coreg IR only 2. Coreg CR only 3. Long acting beta-blockers (LA propranolol and S.A. metoprolol) 4. other α1/βadrenergic antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol 5. Short acting Non-selective beta-blockers
2 and short acting β1-selective agents 6. ACEi only 7. ACEi plus Coreg IR 8. ACEi plus Coreg CR 9.ACEi plus (long acting beta-blockers, labetolol, Short acting Non-selective beta-blockers or short acting β1-selective agents) 10. No beta-blocker or ACEi use 11. Other, i.e, does not fit in any of the above ten categories Non-selective beta-blockers: Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Propranolol / LA propranolol, Sotalol, Timolol β1-selective agents: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol/ S.A.metoprolol Beta Blockers (α1/β-adrenergic antagonists): Carvedilol / IR and CR, Labetalol ACEi: Captopril, Benazepril, Enalapril, Lisinopril, Fosinopril, Ramipril, Perindopril, Quinapril, Moexipril, Trandolapril Outcome definitions and Measures Following are the ICD-9-CM codes for the outcomes (events) of interest: Other anaphylactic shock Angioneurotic edema The 2 ICD-9 codes were combined for the purposes of this analysis. Data Analysis Methods: Descriptive statistics, including age, gender, person-years of follow-up time, co-morbidities and concomitant medications, for the hypersensitivity reaction cases of interest and matched controls as well as the B- blocker users cohort from which they were sampled were calculated. The total follow-up time was calculated for cases by adding the length of time between subject s first beta-blocker prescription date and the hypersensitivity reaction diagnosis date (index date). The follow-up time for controls was defined as the time between the subject s first B- blocker prescription date and the index date of the case to which it was matched. For the cohort of beta-blocker users, unadjusted incidence rates of the hypersensitivity reactions of interest was calculated from the number of patients who developed a hypersensitivity reaction divided by the total person-years of follow-up. Follow-up began on the date of the first prescription of a beta-blocker in subjects who had at least six months of follow-up in the database prior to the first recorded dispensing of beta-blocker. Follow-up shifted between the eleven exposure classes defined above, on the basis of whether each day of follow-up fell within the period defined by the days supply associated with each dispensing of the drug category of interest. In addition, we allowed a 7-day extension past the end of each dispensing (calculated as days supply + 7 ) to account for minor gaps in refilling patterns. Patients were followed from their first beta-blocker prescription date until the first occurrence of any of the following: hypersensitivity reaction diagnosis; death; disenrollment from the health plan; or end of study period (Sep. 30 th, 2007). Other risk factors for hypersensitivity reaction adjusted for in this analysis include: age; gender; history of drug/food/or other allergies; respiratory disorders/asthma; cardiac disease; drugs with recognized risk of serious hypersensitivity such as NSAID, salicylates, antibiotics including penicillin and sulfonamides; inhaled beta-agonists (surrogate for bronchospastic disease); angiotensin receptor blockers (ARB) use. All analyses were conducted using SAS version 9 (SAS institute, Inc., Cary, N.C.). The following analyses were conducted to address each of the objectives: 1. To assess whether Coreg CR is associated with a higher risk of hypersensitivity reactions compared to Coreg IR. The reference group was Coreg IR. Odds ratios with 95% confidence intervals comparing Coreg CR to Coreg IR were generated using conditional logistic regression. In addition to the matching variables, the analyses were adjusted for other hypersensitivity reaction risk factors listed above. 2. To assess whether Coreg CR is associated with a higher risk of hypersensitivity reactions compared to other long acting B-blockers. The reference category was a combined cohort of LA propranolol and S.A. metoprolol. Odds ratios comparing Coreg CR to other long acting B-blockers (LA propranolol and S.A. metoprolol) were generated using conditional logistic regression. In addition to the matching variables, the analyses were adjusted for other hypersensitivity reaction risk factors listed above. 3. To assess whether switching from Coreg IR to Coreg CR is associated with a higher risk of hypersensitivity reactions compared to switching from Coreg IR to other long acting B-blockers. The reference group was switchers from Coreg IR to other long acting B-agonists (LA propranolol and S.A. metoprolol). The following exposure categories were created based on prescription dates: a. switchers from Coreg IR to Coreg CR b. switchers from Coreg IR to other long acting beta-blockers (LA propranolol
3 and S.A. metoprolol) c. all other switchers between various beta-blockers d. non-switchers e. no beta-blocker use Switching was accessed based on dates of prescription claims in the one month prior to index date. This is best illustrated by an example. For a subject (case or control) with a prescription for Coreg CR within one month prior to the index date, we would look back in the month prior to the prescription date for the Coreg CR. If this subject had a script for Coreg IR, he would be considered a switcher from Coreg IR to Coreg CR. Limitations: There are several limitations to the present study. The size of the Coreg CR cohort is relatively small (8744 exposed subjects with 8 cases of hypersensitivity reactions exposed to Coreg CR and 10 controls). Since Coreg CR was launched in March of 2007, subjects exposed to Coreg CR have shorter follow-up compared to the other cohorts captured in this study. This reduces the precision of our estimates. Further, beta blocker and ACEi exposure was inferred from prescription claims in the 1 month prior to the index date. We did not analyze data on prescriptions prior to this 1-month period. Therefore, we do not know if the subject had a previous prescription of the product that carried over into this 1-month window. We also do not know how long subjects were exposed to their medication or if they have recently switched medications. Additionally, while the medication was dispensed, it is not possible to determine whether patients actually consumed the prescribed medication. In addition, ICD9 codes were used to identify subjects with hypersensitivity reactions. These codes were reviewed by a clinician. However, a validation with chart review to confirm the hypersensitivity diagnoses was not performed. A claims based adjudication of the diagnosis of hypersensitivity reactions was conducted.
4 Study Results: A total of 1.3 million beta-blocker users were identified (Table 1). The beta-blocker cohort had equal representation of males and females. The average follow-up was 1.4 years. Fifty-seven percent of the cohort were years of age. Eighty percent had cardiac disease and 16% had respiratory disorders during their follow-up. Among this cohort, 4,441 cases of hypersensitivity reactions were identified and matched to 13,323 controls (Table 1). The unadjusted incidence rate of hypersensitivity reactions among the beta-blocker cohort was 2.38 events per 1,000 person-years (95% CI= ) (Table 2). The incidence rate of hypersensitivity reactions was higher among females (2.72 per 1,000 person-years (95% CI= )) compared to males (2.05 per 1,000 person-years (95% CI= )). The incidence rate was similar for the various age groups. The incidence rate of hypersensitivity reactions however was different for the various exposure categories and ranged from 2.07 per 1,000 person-years (95% CI= ) for short acting selective/non-selective beta-blockers to 5.89 per 1,000 person-years (95% CI= ) for Coreg CR (Table 3). The rates of hypersensitivity reactions among the various exposure categories are NOT adjusted for the baseline differences in comorbid conditions and drug exposures known to be associated with increased risk of hypersensitivity reactions. Table 4 represents the likelihood of developing hypersensitivity reactions for the various exposure categories of interest compared to Coreg IR among the beta-blocker users cohort. Compared to Coreg IR, the unadjusted odds ratio for hypersensitivity reactions in Coreg CR users was 2.15 (95% CI = ), indicating a 2.15 fold increased likelihood of hypersensitivity reactions in Coreg CR users compared to Coreg IR. However, after adjustment for risk factors for hypersensitivity reactions, the odds of a hypersensitivity reaction was 0.92 (95% CI= ) indicating a similar likelihood of a hypersensitivity reaction in Coreg CR users compared to Coreg IR users. After adjustment for risk factors for hypersensitivity rxns, ACEi plus (long acting beta blockers, labetolol, Short acting Non-selective beta-blockers or short acting β1-selective agents) was associated with 46% increased likelihood of hypersensitivity reactions (OR=1.46; 95% CI= ) compared to Coreg IR. As expected, respiratory disorders including asthma, cardiac disease, history of drug/food or other allergies, NSAID use, antibiotics (penicillin and sulfonamides) and inhaled beta-agonists were all associated with a significantly increased likelihood of developing hypersensitivity reactions. Table 5 displays the likelihood of hypersensitivity reactions for the various exposure categories of interest compared to other long acting beta-blockers among the beta-blocker users cohort. Similar to the previous table, the unadjusted odds ratio for hypersensitivity reactions in Coreg CR users was 2.2 fold higher than that of other long acting beta-blockers (OR= 2.20; 95% CI = ). However, after adjustment for risk factors for hypersensitivity reactions, there was no difference in the likelihood of a hypersensitivity reactions in Coreg CR users compared to other long acting betablockers (OR =0.96; 95% CI= ). The use of ACEi (OR=1.36; 95% CI= ), ACEi plus Coreg IR (OR=1.5; 95% CI= ) and ACEi plus (long acting beta blockers, labetolol, Short acting Non-selective B-Blockers or short acting β1-selective agents) (OR=1.53; 95% CI= ) were associated with 36%, 50% and 53% increased likelihood of developing hypersensitivity reactions, respectively, compared to long acting beta-blocker. Table 6 displays the prevalence of risk factors for hypersensitivity reactions among the cases and controls for the various exposure categories within the beta-blocker cohort. Among the cases, Coreg CR exposed subjects had a high proportion of respiratory disorders/asthma (37.5%), cardiac disease (100%), history of drug/food or other allergies (50%), NSAID use (12.5%), penicillin use (12.5%), inhaled beta-agonist (12.5%) and ARB use (37.5%). Similarly among the controls, Coreg CR exposed subjects had the highest prevalence of respiratory disorders/asthma (30%), cardiac disease (100%) and NSAID (10%) and penicillin use (10%). In addition, comorbid conditions and exposure to drugs in the one year preceding exposure to the drug exposure categories of interest within the Beta-blockers cohort were assessed (Table A in the Appendix). It is apparent that Coreg CR exposed subjects are among the highest cohorts studied in terms of the proportion of subjects with cardiac disease, salicylate use and ARB use. Table 7 displays the number and % of switchers (from Coreg IR to Coreg CR, from Coreg IR to other long acting B- blockers, switchers between other various B-blockers) in LabRx database, among the cases and controls of hypersensitivity reactions. The majority of the cases of hypersensitivity reactions were non-switchers (76.78%) based on an evaluation of switching patterns in the one month prior to the index date. Only one case was a switcher from Coreg IR to Coreg CR. Therefore, it is not possible to address whether switching from Coreg IR to Coreg CR is associated with a higher risk of hypersensitivity reactions compared to switching from Coreg IR to other long acting B- blockers. Conclusion: The results of this study show that exposure to Coreg CR is not associated with an increased likelihood of hypersensitivity reactions (anaphylactic reaction/ angioedema) compared to Coreg IR or other long acting B-blockers.
5 Table 1. Descriptive Statistics of the Beta-Blocker Users Cohort, Hypersensitivity Reactions Cases and Controls in the LabRx database, Beta-blocker Users Cohort N= % Hypersensitivity Rxns Cases N= % Hypersensitivity Rxns Controls N= % Mean SD Mean SD Mean SD Age (years) Follow-up (years) Gender N % N % N % Male Female Age category < > Co-Morbidities* Respiratory disorders/ asthma Cardiac disease History of drug/food/or other allergies Concomitant Meds* Salicylates
6 NSAID Penicillin Sulfonamides Inhaled Beta agonists ARB use *For the beta-blocker users cohort, the prevalence of co-morbidities and concomitant medications are calculated if reported at any time during the follow-up. For the cases and controls, the prevalence of co-morbidities is calculated if reported within 3 month prior to the index date and concomitant medications within 1 month prior to the index date. Table 2. Unadjusted Incidence Rate of Hypersensitivity Rxns in the Beta-Blocker Users Cohort According to Gender and Age in the LabRx database, N Events* Person- Years IR** 95% CI Total Gender Male Female Age category < > * Defined as ICD-9 codes for Hypersensitivity Rxns (995.0 for anaphylactic reaction/ for angioneurotic edema) * *per 1,000 person-years Table 3. Unadjusted Incidence Rate of Hypersensitivity Rxns according to exposure category in the month prior to the index date: LabRx database, N Events* Person-Years IR** 95% CI Total 1,327,
7 Coreg IR 67, , Coreg CR 8, , Long acting beta blockers (LA propranolol and S.A. metoprolol) Other α1/β-adrenergic antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol Short acting Non-selective B- Blockers and short acting β1- Selective agents 378, , , , , , ACEi 269, , ACEi plus Coreg IR 45, , ACEi plus Coreg CR 4, , ACEi plus (long acting beta blockers, labetolol, Short acting Non-selective B-Blockers or short acting β1-selective agents) 356, , Other 57, , No B-blocker or ACEi use 1,327, , * Defined as ICD-9 codes for Hypersensitivity Rxns (995.0 for anaphylactic reaction/ for angioneurotic edema) * *per 1,000 person-years Table 4. Odds of Hypersensitivity Reactions for the Various Exposure Categories of Interest compared to Coreg IR users among B-blocker users cohort in the month prior to the index date: LabRx database, Case Control Unadjusted OR [95% n=4441 n=13323 CI] Adjusted OR** [95% CI] (100%) Coreg IR 73 (100%) (1.64%) Coreg CR 8 (1.49%) 10 (Reference group) (Reference group) 2.15( 0.82, 5.66) 0.92( 0.22, 3.74) Long acting beta blockers (LA propranolol and S.A. metoprolol) (0.18%) 501 (11.28%) (0.08%) 1367 (10.26%) 0.97( 0.73, 1.30) 0.96( 0.67, 1.36)
8 Other α1/β-adrenergic 34 antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol (0.77%) Short acting Non-selective B Blockers and short acting β1- Selective agents (23.51%) ACEi 296 (6.67%) ACEi plus Coreg IR 73 (1.64%) ACEi plus Coreg CR 5 ACEi plus (long acting beta blockers, labetolol, Short acting Non-selective B- Blockers or short acting β1- Selective agents) (0.11%) 719 (16.19%) Other 5 (0.11%) No B-blocker or ACEi use (0.71%) 3417 (25.65%) 645 (4.84%) 154 (1.16%) 7 (0.05%) 1377 (10.34%) 8 (0.06%) ( 0.57, 1.48) 0.86( 0.47, 1.56) 0.80( 0.61, 1.06) 0.81( 0.58, 1.14) 1.23( 0.91, 1.66) 1.30( 0.90, 1.89) 1.29( 0.88, 1.90) 1.43( 0.89, 2.29) 1.95( 0.60, 6.35) 2.02( 0.49, 8.26) 1.40( 1.06, 1.86) 1.46( 1.03, 2.07) 1.67( 0.53, 5.29) 2.46( 0.62, 9.76) 0.73( 0.55, 0.96) 0.80( 0.57, 1.13) (37.90%) (45.37%) Age 0.99( 0.98, 1.01) Respiratory disorders/ asthma 961 (21.64%) Cardiac disease 3320 History of drug/food/or other allergies (74.76%) 1562 (35.17 %) Salicylates 16 (0.36%) NSAID 342 (7.70%) Penicillin 151 (3.40%) Sulfonamides 3 (0.07%) Inhaled Beta agonists 159 (3.58%) 650 (4.88%) 6323 (47.46%) 127 (0.95%) 44 (0.33%) 704 (5.28%) 277 (2.08%) 22 (0.17%) 173 (1.30%) 3.88( 3.34, 4.49) 3.17( 2.87, 3.51) 49.46(39.53, 61.89) 1.03( 0.50, 2.15) 1.48( 1.25, 1.77) 1.34( 1.03, 1.75) 0.26( 0.07, 0.99) 1.36( 1.00, 1.83)
9 ARB use 458 (10.31%) 1217 (9.13%) 1.03( 0.88, 1.19) ** Adjusted for age, gender, index-year, history of drug/food/other allergies, respiratory disorders/ asthma, cardiac disease, aspirin, penicillin, sulfonamides, beta agonists and ARB use Table 5. Odds of Hypersensitivity Rxns for the Various Exposure Categories of Interest compared to Other Long Acting B-blockers in the month prior to the index date: LabRx database, Long acting Beta blockers (LA propranolol and S.A. metoprolol) Case Control Unadjusted OR [95% CI] n=4441 n=13323 (100%) (100%) (Reference group) (11.28%) (10.26%) Adjusted OR** [95% CI] 1.00 (Reference group) Coreg CR 8 (0.18%) Coreg IR (0.08%) ( 0.86, 5.64) 0.96( 0.24, 3.81) 1.03( 0.77, 1.37) 1.05( 0.73, 1.49) Other α1/β-adrenergic antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol (1.64%) 34 (0.77%) (1.49%) 94 (0.71%) 0.94( 0.63, 1.41) 0.90( 0.54, 1.50) Short acting Non-selective B- Blockers and short acting β1- Selective agents 1044 (23.51%) 3417 (25.65%) 0.83( 0.73, 0.94) 0.85( 0.72, 1.00) ACEi 296 (6.67%) ACEi plus Coreg IR 73 (1.64%) ACEi plus Coreg CR (4.84%) 154 (1.16%) ( 1.06, 1.49) 1.36( 1.10, 1.70) 1.32( 0.98, 1.78) 1.50( 1.04, 2.16) 2.00( 0.63, 6.35) 2.11( 0.53, 8.36) ACEi plus (long acting beta blockers, labetolol, Short acting Non-selective B- Blockers or short acting β1- Selective agents) (0.11%) 719 (16.19%) (0.05%) 1377 (10.34%) 1.44( 1.25, 1.65) 1.53( 1.28, 1.83) Other 5 (0.11%) 8 (0.06%) 1.71( 0.56, 5.28) 2.57( 0.67, 9.87)
10 No B-blocker or ACEi use ( 0.66, 0.84) 0.84( 0.72, 0.98) (37.90%) (45.37%) Age 0.99( 0.97, 1.00) Respiratory disorders/ asthma 961 (21.64%) Cardiac disease 3320 History of drug/food/or other allergies (74.76%) 1562 (35.17 %) Salicylates 16 (0.36%) NSAID 342 (7.70%) Penicillin 151 (3.40%) Sulfonamides 3 (0.07%) Inhaled Beta agonists 159 (3.58%) ARB use 458 (10.31%) 650 (4.88%) 6323 (47.46%) 127 (0.95%) 44 (0.33%) 704 (5.28%) 277 (2.08%) 22 (0.17%) 173 (1.30%) 1217 (9.13%) 3.88( 3.34, 4.49) 3.17( 2.87, 3.51) 49.46(39.53, 61.89) 1.03( 0.50, 2.15) 1.48( 1.25, 1.77) 1.34( 1.03, 1.75) 0.26( 0.07, 0.99) 1.36( 1.00, 1.83) 1.03( 0.88, 1.19) ** Adjusted for age, gender, index-year, history of drug/food/other allergies, respiratory disorders/asthma, cardiac disease, aspirin, penicillin, sulfonamides, beta agonists and ARB use.
11 Table 6: Prevalence of risk factors for hypersensitivity reactions among cases and controls in various exposure categories within the beta-blocker cohort in the LabRX database, Respiratory disorders/ asthma Cardiac disease History of drug/food/or other allergies Salicylates NSAID Penicillin Sulfonamides Inhaled Beta agonists ARB use Cases Coreg IR 73 Coreg CR 8 Long acting beta blockers (LA propranolo l and S.A. metoprolol) Other α1/βadrenergic antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol Short acting Nonselective B- Blockers and short acting β1- Selective agents ACEi 296 ACEi plus 73 Coreg IR ACEi plus Coreg CR 5 ACEi plus (long acting beta blockers, labetolol, Short acting Nonselective B- Blockers or short acting β1-selective 719 agents) 14 (19.2) 3 (37.5) 98 (19.6) 13 (38.2) 229 (21.9) 47 (15.9) 11 (15.1) 0 (0.0) 94 (13.1) 63 (86.3) 8 (100.0) 368 (73.5) 30 (88.2) 772 (73.9) 266 (89.9) 68 (93.2) 5 (100.0) 635 (88.3) 17 (23.3) 0 (0.0) 3 (4.1) 3 (4.1) 0 (0.0) 5 (6.8) 4 (50.0) 0 (0.0) 188 (37.5) 1 (0.2) 1 (12.5) 43 (8.6) 1 (12.5) 0 (0.0) 1 (12.5) 16 (3.2) 1 (0.2) 10 (2.0) 9 (26.5) 0 (0.0) 1 (2.9) 1 (2.9) 0 (0.0) 2 (5.9) 400 (38.3) 3 (0.3) 77 (26.0) 3 (1.0) 93 (8.9) 31 (10.5) 35 (3.4) 1 (0.1) 56 (5.4) 9 (3.0) 0 (0.0) 11 (3.7) 15 (20.5) 1 (1.4) 7 (9.6) 4 (5.5) 0 (0.0) 1 (1.4) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 195 (27.1) 4 (0.6) 75 (10.4) 25 (3.5) 0 (0.0) 25 (3.5) Other 5 0 (0.0) 4 (80.0) 1 (20.0) 0 (0.0) 1 0 (0.0) 0 (0.0) 0 (0.0) 4 22 (30.1) 3 (37.5) 90 (18.0) 8 (23.5) 159 (15.2) 13 (4.4) 7 (9.6) 0 (0.0) 36 (5.0)
12 Respiratory disorders/ asthma Cardiac disease History of drug/food/or other allergies Salicylates NSAID Penicillin Sulfonamides Inhaled Beta agonists ARB use No B- blocker or ACEi use (26.9) 1,101 (65.4) 655 (38.9) 4 (0.2) (20.0) (80.0) 87 (5.2) 57 (3.4) 1 (0.1) 48 (2.9) 116 (6.9) Contro ls n (%) Coreg IR 199 Coreg CR 10 Long acting beta blockers (LA propranolo l and S.A. metoprolol) Other α1/βadrenergic antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol Short acting Nonselective B- Blockers and short acting β1- Selective agents ACEi 645 ACEi plus 154 Coreg IR ACEi plus Coreg CR 7 ACEi plus (long acting beta blockers, labetolol, Short acting Nonselective B- Blockers or short acting 1377 β1-selective 13 (6.5) 3 (30.0) 83 (6.1) 4 (4.3) 143 (4.2) 39 (6.0) 7 (4.5) 142 (71.4) 10 (100.0) 698 (51.1) 56 (59.6) 1,638 (47.9) 410 (63.6) 105 (68.2) 0 (0.0) 1 (0.5) 8 (4.0) 7 (3.5) 0 (0.0) 3 (1.5) 0 (0.0) 0 (0.0) 16 (1.2) 5 (0.4) 1 (10.0) 86 (6.3) 1 (10.0) 0 (0.0) 0 (0.0) 24 (1.8) 1 (0.1) 24 (1.8) 1 (1.1) 0 (0.0) 5 (5.3) 4 (4.3) 1 (1.1) 2 (2.1) 34 (1.0) 11 (0.3) 5 (0.8) 1 (0.2) 224 (6.6) 39 (6.0) 72 (2.1) 8 (0.2) 45 (1.3) 10 (1.6) 1 (0.2) 6 (0.9) 1 (0.6) 0 (0.0) 7 (4.5) 4 (2.6) 0 (0.0) 2 (1.3) 1 (14.3) 5 (71.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 51 (3.7) 820 (59.5) 13 (0.9) 7 (0.5) 80 (5.8) 34 (2.5) 3 (0.2) 27 (2.0) 74 (37.2) 2 (20.0) 275 (20.1) 18 (19.1) 399 (11.7) 27 (4.2) 5 (3.2) 0 (0.0) 59 (4.3)
13 Respiratory disorders/ asthma Cardiac disease History of drug/food/or other allergies Salicylates NSAID Penicillin Sulfonamides Inhaled Beta agonists ARB use agents) Other No B- blocker or ACEi use (0.0) 7 (87.5) 0 (0.0) 0 (0.0) 306 (5.1) 2,432 (40.2) 57 (0.9) 19 (0.3) 1 (12.5) 253 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 121 (2.0) 8 (0.1) 64 (1.1) 1 (12.5) 357 (5.9)
14 Table 7. Number and % of switchers* (from Coreg IR to Coreg CR, from Coreg IR to other long acting B-blockers, switchers between other various B-blockers) in LabRx database, among the cases and controls of hypersensitivity reactions. Switchers from Coreg IR to Coreg CR Switchers from Coreg IR to other long acting B-blockers (LA propranolol and S.A. metoprolol) All other switchers between various B-blockers Case Control n=4441 n=13323 (100%) (100%) 1 5 (0.02%) (0.04%) 0 (0.00%) 82 (1.85%) Non-switchers 3410 (76.78%) no B-blocker use 948 (21.35%) 2 (0.02%) 178 (1.34%) 9343 (70.13%) 3795 (28.48%) * SWITCHING PATTERNS WERE EVALUATED IN THE ONE MONTH PRIOR TO THE INDEX DATE
15 Appendix Table A. Number and % of subjects with various comorbidities and drug exposures in the one year preceding exposure to the drug exposure categories of interest within the Beta-blockers cohort: Coreg IR Coreg CR Long acting beta blockers (LA propranolol and S.A. metoprolol) Total N 67,631 Respiratory disorders/ asthma 14,615 (21.6) 8,743 1,580 (18.1) 378,585 78,434 (20.7) Cardiac disease 64,689 (95.6) 8,427 (96.4) 332,467 (87.8) History of drug/food/or other allergies Salicylates 3,541 (5.2) 1,736 (2.6) NSAID 100 (0.1) Penicillin 1,310 (1.9) Sulfonamides 94 (0.1) Inhaled Beta agonists 847 (1.3) 392 (4.5) 306 (3.5) 1 (0.0) 181 (2.1) 7 (0.1) 83 (0.9) 24,000 (6.3) 12,148 (3.2) 486 (0.1) 8,535 (2.3) 516 (0.1) 4,093 (1.1) ARB use 3,280 (4.8) 670 (7.7) 16,211 (4.3) Other α1/βadrenergic antagonists (excluding Coreg IR and Coreg CR), i.e., labetalol Short acting Nonselective B-Blockers and short acting β1- Selective agents 30,848 5,793 (18.8) 927, ,043 (18.3) 25,932 (84.1) 771,545 (83.2) 1,740 (5.6) 1,253 (4.1) 51,219 (5.5) 27,208 (2.9) 53 (0.2) 1,348 (0.1) 858 (2.8) 39 (0.1) 18,242 (2.0) 1,094 (0.1) 407 (1.3) 9,521 (1.0) 1,333 (4.3) 27,533 (3.0) ACEi ACEi plus Coreg IR ACEi plus Coreg CR 268,743 51,655 (19.2) 45,368 9,157 (20.2) 4, (16.5) 258,756 (96.3) 43,773 (96.5) 4,273 (97.6) 14,446 (5.4) 6,236 (2.3) 2,115 (4.7) 776 (1.7) 396 (0.1) 62 (0.1) 4,097 (1.5) 275 (0.1) 665 (1.5) 45 (0.1) 2,553 (0.9) 425 (0.9) 175 (4.0) 76 (1.7) 0 (0.0) 58 (1.3) 1 (0.0) 28 (0.6) 5,171 (1.9) 750 (1.7) 99 (2.3)
16 ACEi plus (long acting beta blockers, labetolol, Short acting Non-selective B-Blockers or short acting β1-selective agents) Total N 356,631 Respiratory disorders/ asthma 61,491 (17.2) Cardiac disease 334,583 (93.8) History of drug/food/or other allergies Salicylates 17,530 (4.9) 7,979 (2.2) NSAID 519 (0.1) Penicillin 5,151 (1.4) Sulfonamides 371 (0.1) Inhaled Beta agonists 3,081 (0.9) ARB use 6,428 (1.8) Other No B-blocker or ACEi use 57,197 1,043,528 12,139 (21.2) 207,599 (19.9) 52,434 (91.7) 894,410 (85.7) 3,554 (6.2) 1,677 (2.9) 62,582 (6.0) 33,637 (3.2) 91 (0.2) 1,593 (0.2) 1,211 (2.1) 23,408 (2.2) 84 (0.1) 1,366 (0.1) 584 (1.0) 11,846 (1.1) 2,651 (4.6) 36,162 (3.5)
Brookings Roundtable on Active Medical Product Surveillance:
2012, The Brookings Institution Brookings Roundtable on Active Medical Product Surveillance: Findings from a Mini-Sentinel Medical Product Assessment Marsha Reichman, U.S. Food and Drug Administration
More informationCodes for a Medicare claims-based model to predict LVEF class- User Guide
Description and citation: This guide accompanies our manuscript [Desai RJ, Lin KJ, Patorno E, et al. Development and Preliminary Validation of a Medicare Claims Based Model to Predict Left Ventricular
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationFactors Involved in Poor Control of Risk Factors
Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter
More informationHEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications
HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications Fidelis SecureCare strives to provide quality healthcare to our membership as measured through HEDIS quality metrics.
More informationAntihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
More informationASEBP and ARTA TARP Drugs and Reference Price by Categories
ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationHEDIS. Quick Reference Guide. For more information, visit
HEDIS Quick Reference Guide For more information, visit www.ncqa.org HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2017 Technical Specifications Michigan Complete Health Medicare-Medicaid Plan
More informationUse of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge
RESEARCH Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge Helen Y. Lee, PharmD, MBA; Catherine E. Cooke, PharmD, BCPS, PAHM; and Teisha A. Robertson,
More informationIntegrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year. Risk of seizures associated with Ranolazine (Ranexa)
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Risk of seizures associated with Ranolazine (Ranexa) Efe Eworuke, PhD Division of Epidemiology Office of Pharmacovigilance
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationConversion of losartan to lisinopril
Cari untuk: Cari Cari Conversion of losartan to lisinopril Dania Alsammarae, Strategy Director and co-founder of Anglo Arabian Healthcare speaks with Neil Halligan of Arabian Business on what it takes
More information*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.
Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More information2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) 2014 PQRS OPTIONS F INDIVIDUAL MEASURES:
More information*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.
Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality
More informationHEDIS. Quick Reference Guide. For more information, visit
HEDIS Quick Reference Guide For more information, visit www.ncqa.org HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2018 Technical Specifications Michigan Complete Health strives to provide
More informationJacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,
More informationLisinopril losartan conversion dose
P ford residence southampton, ny Lisinopril losartan conversion dose Deep in-house technology, streaming expertise, and partnerships with the widest range of digital platforms secures our position as the
More informationDeveloped by Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed : October 2009 Most recently updated: September 2011
Developed by Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed : October 2009 Most recently updated: September 2011 To identify the patients who should receive a beta blocker
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationNo Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 4 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION No
More informationBeta-Blocker Use and Morbidity from Chronic Lung Disease in Patients Undertaking Pulmonary Rehabilitation
Beta-Blocker Use and Morbidity from Chronic Lung Disease in Patients Undertaking Pulmonary Rehabilitation by Robert Gabriel Varadi A thesis submitted in conformity with the requirements for the degree
More informationFlorida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013
Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 QUALITY PERFORMANCE METRIC CALCULATION QUALITY METRICS SELECTED FOR MEASUREMENT Per Section 3.2 of the Agreement, HCPP must meet the following
More informationLiving with Congestive Heart Failure: A Guide to a Healthy Heart
Living with Congestive Heart Failure: A Guide to a Healthy Heart Things to Know, Before You Go Dear Patient/Caregiver These are the things you NEED TO KNOW, BEFORE YOU GO. It is very important that you
More information*NOTE: When reporting C P T code and 99239, it is recommended the measure be reported each time the code is submitted for hospital discharge.
Measure #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 2014 PQRS OPTIONS
More informationGeneric Drugs: What does equal really mean? Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre
Generic Drugs: What does equal really mean? Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationCardiac Medications At A Glance
Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationPERSISTENCE OF BETA BLOCKER TREATMENT AFTER A HEART ATTACK
PERSISTENCE OF BETA BLOCKER TREATMENT AFTER A HEART ATTACK APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? HEDIS (Administrative) NCQA Accreditation (Medicare
More informationAntihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
More information100 mg atenolol equivalent to metoprolol
100 mg atenolol equivalent to metoprolol Metoprolol is a selective beta-blocker at dosages usually prescribed to lower blood. For High Blood Pressure For 7 years I have been on 50 mg. of atenolol for.
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationManagement of Heart Failure: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians
Performance Measurement Management of Heart Failure: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians Writing Committee Amir Qaseem, MD,
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationTarget dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic
Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic June Chen 1, Charlotte Galenza 1, Justin Ezekowitz 2,3,
More informationThe ADDITION Study: A study about screening for diabetes. Screening Case Report Form
ADDITION Study, Leicester Participant Identification Label: Date: / / The ADDITION Study: A study about screening for diabetes Screening Case Report Form You will need to have the following things done
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBeta blockers in primary hypertension. Dr. Md. Billal Alam Associate Professor of Medicine DMC
Beta blockers in primary hypertension Dr. Md. Billal Alam Associate Professor of Medicine DMC Development of antihypertensive drugs Beta blockers 1958 - The first beta-blocker, dichloroisoproterenol, was
More informationClinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18
Clinical Policy: Reference Number: CP.PMN.61 Effective Date: 08.01.14 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationImpact of hospitalization on medication adherence estimation in claims data
Received: 23 December 2016 Accepted: 15 February 2017 DOI: 10.1111/jcpt.12517 ORIGINAL ARTICLE Impact of hospitalization on medication adherence estimation in claims data Y.-H. Dong PhD 1,2,3 N. K. Choudhry
More informationClinical Policy: Ranolazine (Ranexa) Reference Number: CP.PMN.34 Effective Date: Last Review Date: 02.19
Clinical Policy: (Ranexa) Reference Number: CP.PMN.34 Effective Date: 08.01.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTexas Prior Authorization Program Clinical Criteria. Allergen Extracts
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Oralair (Mixed Grass Pollens Allergen Extract)) Drugs requiring prior authorization: the
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationAllergy Testing Information
Allergy Testing Information Allergy skin testing takes approximately 1 to 1 ½ hours. Please eat a light breakfast if you are scheduled for a morning appointment. DO NOT SKIP BREAKFAST. If you are scheduled
More informationISMJ International SportMed Journal
32 ISMJ International SportMed Journal FIMS Position Statement Antihypertensive medications and exercise Associate Professor Wayne Derman UCT/MRC Research Unit for Exercise Science and Sports Medicine,
More informationAdrenergic Receptor Antagonists
Adrenergic Receptor Antagonists α-adrenergic Receptor Antagonists Unlike the β-adrenergic receptor antagonists, which bear clear structural similarities to the adrenergic agonists E, epinephrine, and isoproterenol,
More informationDrug Class Review on Beta Adrenergic Blockers
Drug Class Review on Beta Adrenergic Blockers Final Report May 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationLisinopril 20 converting to losartan
Search Lisinopril 20 converting to losartan Stop wasting your time with unanswered searches. lisinopril 40 mg to losartan conversion,cannot Find low price Best. Winds SSW at 10 to 20. Lisinopril 20 to
More informationQTY LIMIT COPAY (30 DAY/90 DAY) BENIGN PROSTATIC HYPERPLASIA FINASTERIDE $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8
2019 LiveWELL Health Plan PREVENTIVE DRUG LIST - GENERIC Names ( Copay) - ALPHABETICAL by DRUG CATEGORY You should always check with your prescriber and/or pharmacist to determine if these alternatives
More informationACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease
ACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease Is This Guide Right for Me? This Guide Is for You If: You have coronary heart disease,
More information2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction
Measure #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationSelect Preventive Prescription Drugs Jan. 1, 2018
Select Preventive Prescription Drugs Jan. 1, 2018 In addition to a healthy lifestyle, preventive medications can help you avoid some illnesses and conditions. Zimmer Biomet's medical options Value HSA,
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationsympathetic nerve impulses endogenous catecholamines beta adrenergic drugs
Beta adrenergic blockers } These drugs will bind and prevent beta-receptors from responding to: sympathetic nerve impulses endogenous catecholamines beta adrenergic drugs the use of beta antagonists is
More informationHEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications
HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications MHS Health Wisconsin strives to provide quality healthcare to our membership as measured through HEDIS quality metrics.
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
More informationMETHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC
PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;
More informationPresenter Disclosure Information
Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationAntihypertensive Agents
Antihypertensive Agents Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 13.11.2009 1 Süzer Farmakoloji 3. Baskı 2005 2 1 Süzer Farmakoloji 3. Baskı 2005 3 Süzer Farmakoloji 3. Baskı 2005
More informationValidity of data sources in pharmacoepidemiology
Validity of data sources in pharmacoepidemiology Jesper Hallas MD DrMedSc Dept of clinical pharmacology University of Southern Denmark, Odense jhallas@health.sdu.dk Disposition 1. Defining validity 2.
More informationLosartan lisinopril equivalent dose
新着 news 2018 年 2 月 28 日 jica 国際協力中学生 高校生エッセイコンテスト 2017 表彰式 2018 年 2 月 19 日 2017 年度第 8 回卒業式を挙行. CHFpatients.com - Ace inhibitors explained in plain English - the primary drug treatment for heart failure
More informationTherapeutics Initiative A SHORT HISTORY
Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription
More informationInitial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO
Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationCilazapril to lisinopril dose conversion
Cilazapril to lisinopril dose conversion The Borg System is 100 % Cilazapril to lisinopril dose conversion COMPARISON OF ANGIOTENSIN CONVERTING ENZYME (ACE). INHIBITORS. Drug. Approximate. Dose. Equivalence.
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Comparative Effectiveness of Different -Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice Alan S. Go, MD; Jingrong Yang, MA; Jerry H. Gurwitz,
More informationAdapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationDrug prescriptions (Pharm) Exposure (36/48 months)
ANNEX SECTION PART A - Study design: Figure 1 overview of the study design Drug prescriptions (Pharm) 2006-2010 Exposure (36/48 months) flexible time windows (e.g. 90 days) time index date (hospital discharge)
More informationLisinopril to losartan equivalent
Your browser does not support script 22-11-2011 Specifically, Lisinopril (brand names include Prinivil and Zestril) is the third most-prescribed drug in the US, according to WebMD Health News (April 20.
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationDisability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors
Outcomes, Health Policy, and Managed Care Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors Yuting Zhang, PhD, a Seo Hyon Baik, PhD, a Chung-Chou H. Chang,
More informationDrug Class Review On Beta Adrenergic Blockers
Drug Class Review On Beta Adrenergic Blockers DRAFT DO NOT QUOTE OR CITE Kim Peterson, MS Mark Helfand, MD, MPH Produced by Oregon Evidence-based Practice Center Oregon Health & Science University 3181
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationRESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access
open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
More informationObservational Study Protocol MB ST
Page: 1 Protocol Number: Date: 28 February 2017 COMPARISON OF THE RISK OF SEVERE COMPLICATIONS OF URINARY TRACT INFECTIONS BETWEEN PATIENTS WITH TYPE 2 DIABETES EXPOSED TO DAPAGLIFLOZIN AND THOSE EXPOSED
More informationHEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications
HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications IlliniCare Health strives to provide quality healthcare to our membership as measured through HEDIS quality metrics.
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationEstimating Medicaid Costs for Cardiovascular Disease: A Claims-based Approach
Estimating Medicaid Costs for Cardiovascular Disease: A Claims-based Approach Presented by Susan G. Haber, Sc.D 1 ; Boyd H. Gilman, Ph.D. 1 1 RTI International Presented at The 133rd Annual Meeting of
More informationAutonomic Pharmacology
Autonomic Pharmacology ADRENERGIC RECEPTOR BLOCKERS Adrenergic-receptor antagonists block the effects of sympathetic stimulation and adrenergic agonists mediated through - and -receptors. Adrenergic receptor
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationextraction can take place. Another problem is that the treatment for chronic diseases is sequential based upon the progression of the disease.
ix Preface The purpose of this text is to show how the investigation of healthcare databases can be used to examine physician decisions to develop evidence-based treatment guidelines that optimize patient
More informationDRUG CLASSIFICATION. Prevention of Cardiovascular Disease
Generic Preventive Care/ Safe Harbor Drug Program List Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition.
More information